Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children

NCT03449836 | Unknown Phase 3

• 1 other identifier: 274/17
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Allergic rhinoconjunctivitis is a pathology of the nasal and conjunctival mucosa induced by Immunoglobulin E (IgE) mediated inflammation following allergic exposure. This condition represents a global health problem that affects 5 to 20% of the population. As with all allergic diseases, its prevalence in pediatric age has increased over the last 30 years, as shown by the results of the international epidemiological study International Study of Asthma and Allergies in Childhood (ISAAC) which shows that the overall prevalence is 8.5 % in children aged 6-7 and 14.6% in children aged 13-14. In Italy, on average, the prevalence stands at 17.6% in the 6-7 year age range and 31.3% in the 13-14 age range, demonstrating a growing trend. The allergic rhinoconjunctivitis undiagnosed and / or not treated properly can negatively affect the school activities and in general the quality of life of children and their parents, as well as having important socio-economic repercussions in terms of medical expenses, school absences and days of work lost by parents. Furthermore, the lack of therapeutic intervention can lead to an increased risk of complications in the medium and long term. Recent advances in the understanding of the mechanisms underlying the inflammation of the airways have led to an improvement of the therapeutic strategies for the management of allergic rhinoconjunctivitis: the four cornerstones of the approach to this pathology promoted by the European Academy of Allergy and Clinical Immunology (EAACI) include allergen removal, patient education, pharmacotherapy and specific immunotherapy. However, there is discordant evidence to support their efficacy in reducing the symptomatology of allergic rhinoconjunctivitis, with the need to resort to the invasive surgical approach in several cases. Therefore, the use of probiotics, defined as "live micro-organisms which, when administered in adequate quantities, confer an advantage for the organism" can be useful. The mechanisms by which probiotics or their components, for example DNA, proteins and peptides, exert such beneficial effects concern the regulation of the immune system, the antagonist action against potentially pathogenic microorganisms and the quantitative and qualitative modulation of the intestinal microbiota. In fact, recent clinical studies have demonstrated the protective effect of infections of the high respiratory tract in adults and recurrent average otitis in pediatric age of the Streptococcus salivarius 24SMBc and Streptococcus oralis 89a strains administered through nasal spray. These well-characterized probiotics were safe, tolerated and able to positively modulate the composition of the respiratory epithelial microbiota and the function of the immune system.

Conditions

Allergy

Outcome Measures

Primary Outcomes (2)

• Total 5 Symptom Score (T5SS) from 0 to 15

  Symptoms evaluation was made by the Total 5 Symptoms Score (T5SS), which includes the symptoms of nasal discharge (rhinorrhea), nasal congestion, itchy nose, sneezing, and itchy eyes. All symptoms were graded from 0 (absent) to 3 (very troublesome),with total scores ranging from 0-15.

  after 20 days of treatment

• Pittsburgh Sleep Quality Index (PSQI) score

  The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Consisting of 19 items, the PSQI measures several different aspects of sleep, offering seven component scores and one composite score. The component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the 7 component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.Traditionally, the items from the PSQI have been summed to create a total score to measure overall sleep quality.

  after 20 days of treatment

Secondary Outcomes (1)

• Evaluation of nasal microbiota composition

  after 20 days of treatment

Study Arms (3)

Streptococcus salivarius 24SMBc + Strept.oralis 89a

EXPERIMENTAL

spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a

Combination Product: Streptococcus salivarius 24SMBc + Strept. oralis 89a

fluticasone + mometasone

ACTIVE COMPARATOR

spray with fluticasone and mometasone

Combination Product: fluticasone + mometasone

placebo

PLACEBO COMPARATOR

spray with isotonic solution

Other: placebo

Interventions

Streptococcus salivarius 24SMBc + Strept. oralis 89a COMBINATION_PRODUCT

nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a

Streptococcus salivarius 24SMBc + Strept.oralis 89a

fluticasone + mometasone COMBINATION_PRODUCT

nasal spray based on fluticasone + mometasone

fluticasone + mometasone

placebo OTHER

nasal spray based on isotonic solution

placebo

Eligibility Criteria

• Age: 6 Years - 12 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• children aged 6-12 months with allergic rhinoconjunctivitis

You may not qualify if:

• concomitant presence of chronic pathologies,
• malformations of the respiratory tract and facial cranium,
• tumors,
• neurological diseases,
• metabolic pathologies,
• cystic fibrosis,
• immunodeficiencies,
• history of epistaxis,
• alteration of coagulation factors,
• history of apnea,
• ciliary dyskinesia,
• treatment with topical drugs nasal steroids and / or oral anti-histaminics or antibiotic treatment in the 3 months prior to enrollment.

Sponsors & Collaborators

• Federico II University: lead

MeSH Terms

Conditions

Hypersensitivity

Interventions

Fluticasone; Mometasone Furoate

Condition Hierarchy (Ancestors)

Immune System Diseases

Intervention Hierarchy (Ancestors)

Androstadienes; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Study Record Dates

• First Submitted: January 25, 2018
• First Posted: February 28, 2018
• Study Start: March 1, 2018
• Primary Completion: September 30, 2018
• Study Completion: December 31, 2018
• Last Updated: March 1, 2018

Record last verified: 2018-02